Invetech, a global leader in instrument development, custom automation, and contract manufacturing, and Biocartis, a diagnostics company focused on improving healthcare outcomes via the practice of personalized medicine, today announced a collaboration agreement to support development and manufacture of Evalution™, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers.
Biocartis’ Evalution™ Multiplex Detection Platform allows researchers in life sciences to analyze a broad range of protein and nucleic-acid based biomarkers.
The Evalution™ platform, designed to support a range of applications in the clinical research and pharmaceutical markets, provides an integrated reaction and detection environment and supports simultaneous analysis of large numbers of analytes per assay. The technology offers real-time visualization of the reaction and data traceability for easy and reliable assay development.
“We first established a collaborative agreement with Biocartis in 2008 when they were a relatively small startup company. Since that time, our team has delivered the full range of our product realization expertise to support their rapid growth and expansion, from project initiation right through to manufacturing. In addition to our instrument development services, we have provided Biocartis with guidance in areas including regulatory, sustaining engineering and instrument service. We look forward to continuing our relationship to help them advance and maximize the potential of the Evalution™ platform in the years ahead,” said David James, Senior Vice President of Diagnostics at Invetech.
Evalution™ is engineered to reduce hands-on time and development complexity, with the potential to streamline procedures for biomarker verification and validation. Currently, Biocartis has multiple scientific collaborations and partnerships in place for the development of novel content on the Evalution™ platform, targeting development of assays in the fields of oncology, cardiology, neurology, and immunology.
“At every stage in our growth, and our focus on product development and manufacturing, our relationship with Invetech has been marked by a high level of collaboration as well as outstanding responsiveness, ease of communication, and flexibility. We look forward to their contributions to the production and expansion of the Evalution™ platform and our efforts to improve data quality, speed to results, and cost-effectiveness in bioassays around the world,” said Paul Ladestein, Managing Director of the Evalution business unit at Biocartis.